FFAR4 and diabetes mellitus: 4-CMTB and GSK137647 were nominated to this study; nevertheless, still, few other FFAR agonists are available, like TUG841, an FFAR4 agonist which is widely investigated in numerous conditions, including diabetes, atherosclerosis, and lung cancer [28, 39, 40].